BACKGROUND: The recurrent immunoglobulin translocation, t(4;14)(p16;q32) occurs in 15% of multiple myeloma patients and is associated with poor prognosis, through an unknown mechanism. The t(4;14) up-regulates fibroblast growth factor receptor 3 (FGFR3) and multiple myeloma SET domain (MMSET) genes. The involvement of MMSET in the pathogenesis of t(4;14) multiple myeloma and the mechanism or genes deregulated by MMSET upregulation are still unclear. DESIGN AND METHODS: The expression of MMSET was analyzed using a novel antibody. The involvement of MMSET in t(4;14) myelomagenesis was assessed by small interfering RNA mediated knockdown combined with several biological assays. In addition, the differential gene expression of MMSET-induced knockdown was analyzed with expression microarrays. MMSET gene targets in primary patient material was analyzed by expression microarrays. RESULTS: We found that MMSET isoforms are expressed in multiple myeloma cell lines, being exclusively up-regulated in t(4;14)-positive cells. Suppression of MMSET expression affected cell proliferation by both decreasing cell viability and cell cycle progression of cells with the t(4;14) translocation. These findings were associated with reduced expression of genes involved in the regulation of cell cycle progression (e.g. CCND2, CCNG1, BRCA1, AURKA and CHEK1), apoptosis (CASP1, CASP4 and FOXO3A) and cell adhesion (ADAM9 and DSG2). Furthermore, we identified genes involved in the latter processes that were differentially expressed in t(4;14) multiple myeloma patient samples. CONCLUSIONS: In conclusion, dysregulation of MMSET affects the expression of several genes involved in the regulation of cell cycle progression, cell adhesion and survival.
BACKGROUND: The recurrent immunoglobulin translocation, t(4;14)(p16;q32) occurs in 15% of multiple myelomapatients and is associated with poor prognosis, through an unknown mechanism. The t(4;14) up-regulates fibroblast growth factor receptor 3 (FGFR3) and multiple myeloma SET domain (MMSET) genes. The involvement of MMSET in the pathogenesis of t(4;14) multiple myeloma and the mechanism or genes deregulated by MMSET upregulation are still unclear. DESIGN AND METHODS: The expression of MMSET was analyzed using a novel antibody. The involvement of MMSET in t(4;14) myelomagenesis was assessed by small interfering RNA mediated knockdown combined with several biological assays. In addition, the differential gene expression of MMSET-induced knockdown was analyzed with expression microarrays. MMSET gene targets in primary patient material was analyzed by expression microarrays. RESULTS: We found that MMSET isoforms are expressed in multiple myeloma cell lines, being exclusively up-regulated in t(4;14)-positive cells. Suppression of MMSET expression affected cell proliferation by both decreasing cell viability and cell cycle progression of cells with the t(4;14) translocation. These findings were associated with reduced expression of genes involved in the regulation of cell cycle progression (e.g. CCND2, CCNG1, BRCA1, AURKA and CHEK1), apoptosis (CASP1, CASP4 and FOXO3A) and cell adhesion (ADAM9 and DSG2). Furthermore, we identified genes involved in the latter processes that were differentially expressed in t(4;14) multiple myelomapatient samples. CONCLUSIONS: In conclusion, dysregulation of MMSET affects the expression of several genes involved in the regulation of cell cycle progression, cell adhesion and survival.
Authors: Matthew W Jenner; Paola E Leone; Brian A Walker; Fiona M Ross; David C Johnson; David Gonzalez; Laura Chiecchio; Elisabet Dachs Cabanas; Gian Paolo Dagrada; Mathew Nightingale; Rebecca K M Protheroe; David Stockley; Monica Else; Nicholas J Dickens; Nicholas C P Cross; Faith E Davies; Gareth J Morgan Journal: Blood Date: 2007-07-03 Impact factor: 22.113
Authors: Josh Lauring; Abde M Abukhdeir; Hiroyuki Konishi; Joseph P Garay; John P Gustin; Qiuju Wang; Robert J Arceci; William Matsui; Ben Ho Park Journal: Blood Date: 2007-10-17 Impact factor: 22.113
Authors: Brian A Walker; Paola E Leone; Matthew W Jenner; Cheng Li; David Gonzalez; David C Johnson; Fiona M Ross; Faith E Davies; Gareth J Morgan Journal: Blood Date: 2006-05-16 Impact factor: 22.113
Authors: Robert Evans; Claudia Naber; Tara Steffler; Tamara Checkland; Jonathan Keats; Christopher Maxwell; Troy Perry; Heidi Chau; Andrew Belch; Linda Pilarski; Tony Reiman Journal: Leuk Lymphoma Date: 2008-03
Authors: Da Wei Huang; Brad T Sherman; Qina Tan; Joseph Kir; David Liu; David Bryant; Yongjian Guo; Robert Stephens; Michael W Baseler; H Clifford Lane; Richard A Lempicki Journal: Nucleic Acids Res Date: 2007-06-18 Impact factor: 16.971
Authors: Richard L Bennett; Alok Swaroop; Catalina Troche; Jonathan D Licht Journal: Cold Spring Harb Perspect Med Date: 2017-06-01 Impact factor: 6.915
Authors: D-J Min; T Ezponda; M K Kim; C M Will; E Martinez-Garcia; R Popovic; V Basrur; K S Elenitoba-Johnson; J D Licht Journal: Leukemia Date: 2012-09-13 Impact factor: 11.528
Authors: Nathan P Coussens; Stephen C Kales; Mark J Henderson; Olivia W Lee; Kurumi Y Horiuchi; Yuren Wang; Qing Chen; Ekaterina Kuznetsova; Jianghong Wu; Sirisha Chakka; Dorian M Cheff; Ken Chih-Chien Cheng; Paul Shinn; Kyle R Brimacombe; Min Shen; Anton Simeonov; Madhu Lal-Nag; Haiching Ma; Ajit Jadhav; Matthew D Hall Journal: J Biol Chem Date: 2018-06-26 Impact factor: 5.157
Authors: Chee Man Cheong; Krzysztof M Mrozik; Duncan R Hewett; Elyse Bell; Vasilios Panagopoulos; Jacqueline E Noll; Jonathan D Licht; Stan Gronthos; Andrew C W Zannettino; Kate Vandyke Journal: Cancer Lett Date: 2020-01-31 Impact factor: 8.679
Authors: Marc-Werner Dobenecker; Jonas Marcello; Annette Becker; Eugene Rudensky; Natarajan V Bhanu; Thomas Carrol; Benjamin A Garcia; Rabinder Prinjha; Vyacheslav Yurchenko; Alexander Tarakhovsky Journal: FEBS Lett Date: 2020-08-29 Impact factor: 4.124